What the FDA labels say about taking them together
Alosetron and leflunomide
Leflunomide's FDA label of June 4, 2025 names alosetron in its drug interactions section; the alosetron label PlainMeds reads does not name leflunomide. The leflunomide label: “In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 may be reduced.”
Check it at the source: the alosetron FDA label on DailyMed (effective March 23, 2026, Legacy Pharma USA Inc.); the leflunomide FDA label on DailyMed (effective June 4, 2025, sanofi-aventis U.S. LLC).
What does the alosetron label say about leflunomide?
Alosetron's label (effective March 23, 2026) does not name leflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LOTRONEX), Legacy Pharma USA Inc., effective March 23, 2026 (SPL set c216e967-436f-475a-8e6a-2ad11adc63af), via openFDA; the full label on DailyMed
What does the leflunomide label say about alosetron?
Leflunomide label, drug interactionsIn patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced.
Source: FDA drug label (Arava), sanofi-aventis U.S. LLC, effective June 4, 2025 (SPL set 320f63f2-fac3-4aee-aff8-85724e00ef52), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Alosetron | Leflunomide | |
|---|---|---|
| Labeled for | n/a | Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $2.02 per tablet 0.5 mg tablet | $0.324 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once